Tuesday, March 26, 2024
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and ABL Bio Co., Ltd. ("ABL") have recently announced a collaborative partnership to advance the development of bispecific antibody-drug conjugates (bsADCs). Biocytogen is a global biotech company specializing in novel antibody therapeutics, while ABL focuses on developing treatments for oncology and central nervous system diseases in South Korea.
The collaboration leverages Biocytogen's RenLite® mouse platform, known for its ability to generate fully human antibodies with diverse epitopes and high affinity. This platform is particularly noteworthy for its use of a common light chain format, which offers advantages for bsADC development. By enhancing design flexibility, simplifying manufacturing processes, and optimizing development efficiency, this innovative technology sets the stage for expanded cooperation between the two companies in developing various ADCs.
Dr. Yuelei Shen, President and CEO of Biocytogen, expressed excitement about partnering with ABL, highlighting ABL's advanced platform in cancer immunotherapy and CNS disease treatment. Dr. Shen emphasized the exceptional efficacy and safety profile demonstrated by bsADC drugs developed from the RenLite® mouse platform across diverse tumor models. Leveraging the platform's features, such as enhanced tumor selectivity and target internalization, combined with ABL's development capabilities, is expected to drive the creation of innovative bsADC therapies, expediting their development process.
Sang Hoon Lee, CEO of ABL, echoed Dr. Shen's sentiments, expressing satisfaction with the collaboration and its potential to advance bsADC development significantly. Lee emphasized the joint effort in building a pioneering pipeline aimed at improving patient outcomes. He expressed confidence in the partnership's ability to contribute meaningfully to the development of new treatments, ultimately enhancing the quality of life for patients.
Source: businesswire.com
